Log in

Relevant bibliographies by topics / Oncologia veterinaria / Journal articles

To see the other types of publications on this topic, follow the link: Oncologia veterinaria.

Journal articles on the topic 'Oncologia veterinaria'

Author: Grafiati

Published: 4 June 2021

Last updated: 31 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Oncologia veterinaria.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

1° CONGRESO INT DE ANESTESIA, ANALGESIA Y ONCOLOGÍA VETER. "Oncología Veterinaria. Trabajos de Investigación y reportes de casos." Ciencia Veterinaria 24, no. 1 especial (December 27, 2022): 1–18. http://dx.doi.org/10.19137/cienvet202224esp02.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Gorinsky, V. I., V. V. Salautin, N. A. Pudovkin, S. D. Klyukin, and S. E. Salautina. "A comprehensive approach to the diagnosis of breast neoplasms in domestic unproductive animals." International Journal of Veterinary Medicine, no. 2 (July 23, 2022): 74–84. http://dx.doi.org/10.52419/issn2072-2419.2022.2.74.

Full text

Abstract:

The spread of oncological diseases is currently one of the main problems in both humanitarian and veterinary medicine. Despite the high achievements of domestic and foreign scientists of modern veterinary medicine in the field of diagnosis, treatment and prevention of oncological processes, the number of cancer-affected animals is quite large and continues to grow steadily. Therefore, improving the complex of diagnostic studies for neoplasms among dogs and cats is one of the priority areas of veterinary medicine. The research was conducted on the basis of the veterinary clinic of the Center for Animal Beauty and Health "Zoostyle" IP Gorinsky V.I. (Volgograd) and the Department of "Morphology, Pathology of Animals and Biology" of the Saratov State Agrarian University. In the period from 2018 to 2021, 244 patients, including 127 dogs and 117 cats, were examined by an oncologist at the veterinary clinic of the Zoostyle Center for Animal Beauty and Health.All the animals belonged to residents of the city of Volgograd. When an animal was admitted to the clinic for an oncological appointment, animals with any visual signs of a neoplasm in the projection of the breast were selected for research. As a result of the physical examination, based on the results of laboratory, X-ray and ultrasound examinations, MR tomography, it was found that breast tumors (OMJ) are more common among dogs and cats. In the population of dogs, OMH accounted for 33.8% (n=43) and 62.4% (n=73) of all cases of oncological pathology in cats. Depending on the gender, breast neoplasia was observed in females - 100%, in cats, females accounted for 89%, and males - 11%. The results obtained indicate that the introduction of a complex of modern high-tech diagnostic methods into veterinary oncology practice is a key element that significantly affects the prospects for providing specialized care and prognosis.

APA, Harvard, Vancouver, ISO, and other styles

3

Matos da Silva, Daniella, and Tilde Rodrigues Froes. "Veterinary oncology: radiology and ultrasonography exams in decision makingOncologia veterinária – exames radiográficos e ultrassonografia na tomada de decisões." Clínica Veterinária XXI, no. 124 (September 1, 2016): 56–76. http://dx.doi.org/10.46958/rcv.2016.xxi.n.124.p.56-76.

Full text

Abstract:

Imaging exams are frequently requested during assessment of oncological patients. Although advanced imaging techniques are already available in veterinary medicine, radiographic and ultrasonographic exams remain the basic diagnostic tools in veterinary oncology. This review describes some considerations to improve clinical approach to animals with neoplastic lesions based on the use of radiographic and ultrasonographic exams. The role of these modalities in screening, diagnosis, staging, treatment choice, and follow-up of cancers is discussed. Additionally, a workflow for some type of tumors is described, such as mediastinal lymphoma in cats, as well as mast cell tumors and osteosarcoma in dogs. Situations that require other techniques are also discussed.

APA, Harvard, Vancouver, ISO, and other styles

4

ŁOJSZCZYK, ANNA, PIOTR DĘBIAK, GRAŻYNA JARZĄBEK-BIELECKA, WITOLD KĘDZIA, and MAŁGORZATA MIZGIER. "Use of positron emission tomography in medicine and veterinary medicine." Medycyna Weterynaryjna 76, no. 04 (2020): 6388–2020. http://dx.doi.org/10.21521/mw.6388.

Full text

Abstract:

Positron emission tomography (PET) is an imaging technique using positron (anti-electron) radiopharmaceuticals, in which radiation generated during the annihilation of positrons is recorded. This method is used in oncology, neurology and cardiology. PET is of particular importance to oncology, in both scientific and clinical research, especially in the identification and staging of metastatic disease, as well as in therapy planning and control. The use of PET has contributed to the advancement of research into many neurological problems. Data in the literature indicate that PET is widely used in veterinary medicine. PET allows for detailed evaluation of many oncologic and fungal diseases. In neurology, it has been used in necrotizing meningoencephalitis and epilepsy. There have been a number of experimental studies in cardiology, as well, in patients after radiation therapy.

APA, Harvard, Vancouver, ISO, and other styles

5

Bennett, PF. "Veterinary Oncology." Australian Veterinary Journal 81, no. 3 (March 2003): 135. http://dx.doi.org/10.1111/j.1751-0813.2003.tb11073.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

HAYES, H. M. "Veterinary Oncology." JNCI Journal of the National Cancer Institute 82, no. 11 (June 6, 1990): 973. http://dx.doi.org/10.1093/jnci/82.11.973.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Smith, T. "Veterinary Oncology." JNCI Journal of the National Cancer Institute 82, no. 4 (February 21, 1990): 327. http://dx.doi.org/10.1093/jnci/82.4.327.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Berlato, Davide, Julie Bulman-Fleming, Craig A. Clifford, Laura Garrett, Joanne Intile, Pamela Jones, Debra A. Kamstock, et al. "Value, Limitations, and Recommendations for Grading of Canine Cutaneous Mast Cell Tumors: A Consensus of the Oncology-Pathology Working Group." Veterinary Pathology 58, no. 5 (April 23, 2021): 858–63. http://dx.doi.org/10.1177/03009858211009785.

Full text

Abstract:

One of the primary objectives of the Oncology Pathology Working Group (OPWG), a joint initiative of the Veterinary Cancer Society and the American College of Veterinary Pathologists, is for oncologists and pathologists to collaboratively generate consensus documents to standardize aspects and provide guidelines for oncologic pathology. Consensus is established through review of relevant peer-reviewed literature relative to a subgroup’s particular focus. In this article, the authors provide a critical review of the current literature for grading of canine cutaneous mast cell tumors, suggest guidelines for reporting, and provide recommendations for its clinical interpretation. The article mainly focuses on histologic grading, but relevant information on mitotic count and cytological grading are also discussed. This document represents the opinions of the working group and the authors but does not constitute a formal endorsement by the American College of Veterinary Pathologists or the Veterinary Cancer Society.

APA, Harvard, Vancouver, ISO, and other styles

9

Balsa, Ingrid, and William Culp. "Use of Minimally Invasive Surgery in the Diagnosis and Treatment of Cancer in Dogs and Cats." Veterinary Sciences 6, no. 1 (March 20, 2019): 33. http://dx.doi.org/10.3390/vetsci6010033.

Full text

Abstract:

Surgical management of neoplastic disease is common in veterinary medicine. Minimally invasive surgery (MIS) has gained widespread acceptance by veterinary surgeons and is experiencing rapid growth and frequency of use. Many neoplastic diseases in the abdomen and thorax of dogs and cats can be treated as effectively with MIS as with traditional open surgery. Additionally, MIS allows for less invasive options for organ biopsy in cancer patients either for initial diagnosis or for staging to inform prognosis and treatment. Despite the recent increase in MIS, additional research is required to further characterize the benefits to oncology patients and to ensure that surgical oncologic principles and patient outcomes are not compromised by the use of MIS.

APA, Harvard, Vancouver, ISO, and other styles

10

Bergman, Philip J. "Veterinary Oncology Immunotherapies." Veterinary Clinics of North America: Small Animal Practice 48, no. 2 (March 2018): 257–77. http://dx.doi.org/10.1016/j.cvsm.2017.10.004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Crînganu, Dan, Raluca Negreanu, and Ionuţ Gârjoabă. "Management of veterinary oncologic emergencies." Practica Veterinara.ro 2, no. 31 (2018): 18. http://dx.doi.org/10.26416/pv.31.2.2018.1854.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Somarelli, Jason A., Amy M. Boddy, Heather L. Gardner, Suzanne Bartholf DeWitt, Joanne Tuohy, Kate Megquier, Maya U. Sheth, et al. "Improving Cancer Drug Discovery by Studying Cancer across the Tree of Life." Molecular Biology and Evolution 37, no. 1 (November 5, 2019): 11–17. http://dx.doi.org/10.1093/molbev/msz254.

Full text

Abstract:

Abstract Despite a considerable expenditure of time and resources and significant advances in experimental models of disease, cancer research continues to suffer from extremely low success rates in translating preclinical discoveries into clinical practice. The continued failure of cancer drug development, particularly late in the course of human testing, not only impacts patient outcomes, but also drives up the cost for those therapies that do succeed. It is clear that a paradigm shift is necessary if improvements in this process are to occur. One promising direction for increasing translational success is comparative oncology—the study of cancer across species, often involving veterinary patients that develop naturally-occurring cancers. Comparative oncology leverages the power of cross-species analyses to understand the fundamental drivers of cancer protective mechanisms, as well as factors contributing to cancer initiation and progression. Clinical trials in veterinary patients with cancer provide an opportunity to evaluate novel therapeutics in a setting that recapitulates many of the key features of human cancers, including genomic aberrations that underly tumor development, response and resistance to treatment, and the presence of comorbidities that can affect outcomes. With a concerted effort from basic scientists, human physicians and veterinarians, comparative oncology has the potential to enhance the cost-effectiveness and efficiency of pipelines for cancer drug discovery and other cancer treatments.

APA, Harvard, Vancouver, ISO, and other styles

13

Stephens, Tanya. "The Use of Chemotherapy to Prolong the Life of Dogs Suffering from Cancer: The Ethical Dilemma." Animals 9, no. 7 (July 14, 2019): 441. http://dx.doi.org/10.3390/ani9070441.

Full text

Abstract:

Despite the emergence some years ago of oncology as a veterinary specialty, there has been very little in the way of ethical debate on the use of chemotherapy in dogs. The purpose of this article is to undertake an ethical analysis to critically examine the use of chemotherapy to prolong the life of dogs suffering from cancer. If dogs have no concept of the future and are likely to suffer at least some adverse effects with such treatments, consideration should be given as to whether it is ethical and in the animal’s best interests to use chemotherapy. Chemotherapeutic drugs are mutagenic, carcinogenic, teratogenic and may be irritant. Furthermore, chemotherapy may involve multiple trips to the veterinarian, multiple procedures and periods in isolation. Cancer-associated pain has been shown to be under-diagnosed and pet owners overestimate the effects of chemotherapy on treatment survival time. Of additional concern is the public health risks associated with chemotherapeutic drugs. As chemotherapy is not generally considered curative, it is in effect palliative care. However, palliative care may not be in the best interests of a terminally ill animal. As the specialty of veterinary oncology continues to grow and as the use of chemotherapy becomes more commonplace in the treatment of animals with cancer, it is imperative that there is an ongoing ethical debate on the use of chemotherapy in animals.

APA, Harvard, Vancouver, ISO, and other styles

14

Cemazar, M., Y. Tamzali, G. Sersa, N. Tozon, L. M. Mir, D. Miklavcic, R. Lowe, and J. Teissie. "Electrochemotherapy in Veterinary Oncology." Journal of Veterinary Internal Medicine 22, no. 4 (July 2008): 826–31. http://dx.doi.org/10.1111/j.1939-1676.2008.0117.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Lin, Tzu-yin, Carlos O. Rodriguez, and Yuanpei Li. "Nanomedicine in veterinary oncology." Veterinary Journal 205, no. 2 (August 2015): 189–97. http://dx.doi.org/10.1016/j.tvjl.2015.02.015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Impellizeri, J., L. Aurisicchio, P. Forde, and D. M. Soden. "Electroporation in veterinary oncology." Veterinary Journal 217 (November 2016): 18–25. http://dx.doi.org/10.1016/j.tvjl.2016.05.015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Bergman, Philip J. "Immunotherapy in Veterinary Oncology." Veterinary Clinics of North America: Small Animal Practice 44, no. 5 (September 2014): 925–39. http://dx.doi.org/10.1016/j.cvsm.2014.05.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Smith, Annette N. "Advances in Veterinary Oncology." Veterinary Clinics of North America: Small Animal Practice 44, no. 5 (September 2014): xi—xii. http://dx.doi.org/10.1016/j.cvsm.2014.06.004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Spugnini, Enrico Pierluigi, and Alfonso Baldi. "Electrochemotherapy in Veterinary Oncology." Veterinary Clinics of North America: Small Animal Practice 49, no. 5 (September 2019): 967–79. http://dx.doi.org/10.1016/j.cvsm.2019.04.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Szweda, Marta, Andrzej Rychlik, Izabella Babińska, and Andrzej Pomianowski. "Cyclooxygenase-2 as a biomarker with diagnostic, therapeutic, prognostic, and predictive relevance in small animal oncology." Journal of Veterinary Research 64, no. 1 (March 24, 2020): 151–60. http://dx.doi.org/10.2478/jvetres-2020-0018.

Full text

Abstract:

AbstractIn canine and feline populations, the number of neoplasm cases continues to increase around the world. Attempts are being made in centres of research to identify new biomarkers that speed up and improve the quality of oncological diagnostics and therapy in human and animal tumour patients. Cyclooxygenase-2 (COX-2) is a promising biomarker with increasing relevance to human oncology, but as yet with less application in veterinary oncology. The expression of COX-2 increases significantly during pathological processes involving inflammation, pain or fever. It is also overexpressed in humans presenting various types of tumours and in selected types of tumours in animals, particularly in dogs. This article discusses the expression of COX-2 in canine and feline tumours, the importance of COX-2 as a biomarker with diagnostic, therapeutic, prognostic and predictive relevance in oncology, and the clinical significance of inhibiting COX-2 overexpression in tumours.

APA, Harvard, Vancouver, ISO, and other styles

21

Nowosh, Victor, and Cristina de O. M. S. Gomes. "Liquid biopsy and its applications in veterinary medicine – a review." Clínica Veterinária XXIV, no. 139 (March 1, 2019): 36–52. http://dx.doi.org/10.46958/rcv.2019.xxiv.n.139.p.36-52.

Full text

Abstract:

Liquid biopsy is a diagnostic and prognostic tool already reported in several studies with human oncologic patients, and shows potential for application in veterinary oncology. However, liquid biopsy is not a widely known technique in veterinary medicine, and related research is sparse. Liquid biopsy is based on the analysis of blood samples for detection of various tumoral products in circulation. It is a non-invasive technique, and provides results in real time. Information obtained from liquid biopsies can complement the information obtained from the analysis of tissue biopsy. In this review of literature, we present the background principles of liquid biopsy, its methodology, and the tumoral products that can currently be detected with this tool. In addition to circulating tumor cells, liquid biopsies allow detection of nucleic acids, including tumor DNA, micro-RNA, messenger RNA and exosomes. We present the value of liquid biopsy as a diagnostic and prognostic tool, its predictive value in tumor progression and treatment success, and usefulness to assist treatment choice. We discuss its limitations, and the challenges to implement its use in a large scale.

APA, Harvard, Vancouver, ISO, and other styles

22

Dobson, Jane. "Recent advances in veterinary oncology." BSAVA Companion 2011, no. 1 (January 1, 2011): 7–9. http://dx.doi.org/10.22233/20412495.0111.7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Vail, David M. "Veterinary Co-operative Oncology Group." Veterinary and Comparative Oncology 2, no. 4 (December 2004): 194. http://dx.doi.org/10.1111/j.1476-5810.2004.0053a.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Reggeti, F., and D. Bienzle. "Flow Cytometry in Veterinary Oncology." Veterinary Pathology 48, no. 1 (September 8, 2010): 223–35. http://dx.doi.org/10.1177/0300985810379435.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Looney, Andrea. "Oncology Pain in Veterinary Patients." Topics in Companion Animal Medicine 25, no. 1 (February 2010): 32–44. http://dx.doi.org/10.1053/j.tcam.2009.10.008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Sao Braz, B. F., J. Palminha, and G. Vicente. "Occupational risk in veterinary oncology." Toxicology Letters 205 (August 2011): S268. http://dx.doi.org/10.1016/j.toxlet.2011.05.911.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Gillette, Edward L. "History of Veterinary Radiation Oncology." Veterinary Clinics of North America: Small Animal Practice 27, no. 1 (January 1997): 1–6. http://dx.doi.org/10.1016/s0195-5616(97)50001-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Gavin, Patrick R. "Future of Veterinary Radiation Oncology." Veterinary Clinics of North America: Small Animal Practice 27, no. 1 (January 1997): 157–65. http://dx.doi.org/10.1016/s0195-5616(97)50014-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Londhe, Priya, Megan Gutwillig, and Cheryl London. "Targeted Therapies in Veterinary Oncology." Veterinary Clinics of North America: Small Animal Practice 49, no. 5 (September 2019): 917–31. http://dx.doi.org/10.1016/j.cvsm.2019.04.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Nolan, Michael W., and Tracy L. Gieger. "Update in Veterinary Radiation Oncology." Veterinary Clinics of North America: Small Animal Practice 49, no. 5 (September 2019): 933–47. http://dx.doi.org/10.1016/j.cvsm.2019.05.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Bergman, Philip J., and Craig A. Clifford. "Recent Advancements in Veterinary Oncology." Veterinary Clinics of North America: Small Animal Practice 49, no. 5 (September 2019): xiii—xiv. http://dx.doi.org/10.1016/j.cvsm.2019.06.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Raluca, Negreanu Elena, Crînganu Dan, Constantinescu Radu, Mirea Dragoş, Dontu Simona, and Negreanu Răzvan. "Developing edges in veterinary oncology." Journal of Biotechnology 208 (August 2015): S40—S41. http://dx.doi.org/10.1016/j.jbiotec.2015.06.114.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Miller, Andrew D., Giancarlo Avallone, James Chambers, and Roberta Rasotto. "Special focus on diagnostic veterinary oncologic pathology." Veterinary Pathology 58, no. 5 (July 1, 2021): 764–65. http://dx.doi.org/10.1177/03009858211027357.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Beer, Patricia, Lavinia E. Chiti, and Mirja C. Nolff. "The Role of Sentinel Node Mapping and Lymphadenectomies in Veterinary Surgical Oncology." Lymphatics 1, no. 1 (January 10, 2023): 2–18. http://dx.doi.org/10.3390/lymphatics1010002.

Full text

Abstract:

Lymph node status is an important prognostic factor in multiple oncologic conditions in humans and companion animals. In addition, the resection of the affected nodes can have a substantial therapeutic effect on various cancer subtypes in both species. Given the impact on prognosis and management, it is paramount to identify and remove affected nodes. While this can be achieved by removing predefined patterns of nodes (regional lymphadenectomy/resection of defined lymphatic stations), modern approaches increasingly utilize sentinel node mapping to identify the draining nodes to decrease the mortality of lymphadenectomies. Recent studies have shown that dogs have more comparable anatomy of the lymphatic system to humans than other animal models such as rodents or pigs. Given the fact that dogs develop spontaneous cancer types that share several similarities to their human counterparts, they represent a valuable translational model. The management of the lymphatic basin and sentinel node mapping have gained increased attention in veterinary surgical oncology in recent years. The present review aims at summarizing the resulting findings and their impact on patient management.

APA, Harvard, Vancouver, ISO, and other styles

35

Giuliano, Antonio, Rodrigo S. Horta, Rafael A. M. Vieira, Kelly R. Hume, and Jane Dobson. "Repurposing Drugs in Small Animal Oncology." Animals 13, no. 1 (December 29, 2022): 139. http://dx.doi.org/10.3390/ani13010139.

Full text

Abstract:

Repurposing drugs in oncology consists of using off-label drugs that are licensed for various non-oncological medical conditions to treat cancer. Repurposing drugs has the advantage of using drugs that are already commercialized, with known mechanisms of action, proven safety profiles, and known toxicology, pharmacokinetics and pharmacodynamics, and posology. These drugs are usually cheaper than new anti-cancer drugs and thus more affordable, even in low-income countries. The interest in repurposed anti-cancer drugs has led to numerous in vivo and in vitro studies, with some promising results. Some randomized clinical trials have also been performed in humans, with certain drugs showing some degree of clinical efficacy, but the true clinical benefit for most of these drugs remains unknown. Repurposing drugs in veterinary oncology is a very new concept and only a few studies have been published so far. In this review, we summarize both the benefits and challenges of using repurposed anti-cancer drugs; we report and discuss the most relevant studies that have been previously published in small animal oncology, and we suggest potential drugs that could be clinically investigated for anti-cancer treatment in dogs and cats.

APA, Harvard, Vancouver, ISO, and other styles

36

Boston, Sarah. "The paradox of veterinary surgical oncology." Veterinary Surgery 50, no. 4 (April 3, 2021): 712. http://dx.doi.org/10.1111/vsu.13631.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Mair, T. "Equine Veterinary Educationvirtual issue on oncology." Equine Veterinary Education 26, no. 3 (February 14, 2014): 115. http://dx.doi.org/10.1111/eve.12151.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Kent, M. S., M. M. Turek, and J. Farrelly. "Recent advances in veterinary radiation oncology." Veterinary and Comparative Oncology 16, no. 2 (January 14, 2018): 167–69. http://dx.doi.org/10.1111/vco.12366.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Breen, Matthew. "Update on Genomics in Veterinary Oncology." Topics in Companion Animal Medicine 24, no. 3 (August 2009): 113–21. http://dx.doi.org/10.1053/j.tcam.2009.03.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Withrow, Stephen J. "The evolution of veterinary surgical oncology." Clinical Techniques in Small Animal Practice 13, no. 1 (February 1998): 1–3. http://dx.doi.org/10.1016/s1096-2867(98)80019-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Casteleyn, Christophe, Sara Prims, Steven Van Cruchten, and Christa Van Ginneken. "Stereology: From astronomy to veterinary oncology." Veterinary Journal 202, no. 1 (October 2014): 3–4. http://dx.doi.org/10.1016/j.tvjl.2014.06.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Bergman, Philip J. "Veterinary Oncology Immunotherapies – A Mini Review." Advances in Small Animal Medicine and Surgery 31, no. 9 (September 2018): 1–3. http://dx.doi.org/10.1016/j.asams.2018.09.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Klahn, Shawna. "Chemotherapy Safety in Clinical Veterinary Oncology." Veterinary Clinics of North America: Small Animal Practice 44, no. 5 (September 2014): 941–63. http://dx.doi.org/10.1016/j.cvsm.2014.05.009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Kent, Michael S., Michelle M. Turek, and John Farrelly. "Recent advances in veterinary radiation oncology." Veterinary Radiology & Ultrasound 59, no. 1 (November 13, 2017): 10–12. http://dx.doi.org/10.1111/vru.12573.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Cloquell, Ana, Isidro Mateo, Stefano Gambera, Martí Pumarola, Ramon Alemany, Javier García-Castro, and Ana Judith Perisé-Barrios. "Systemic cellular viroimmunotherapy for canine high-grade gliomas." Journal for ImmunoTherapy of Cancer 10, no. 12 (December 2022): e005669. http://dx.doi.org/10.1136/jitc-2022-005669.

Full text

Abstract:

BackgroundOncolytic viruses constitute a growing field of interest, both in human and veterinary oncology, given that they are particularly helpful for treating non-surgical tumors and disseminated cancer, such as high-grade gliomas. Companion dogs present malignant gliomas with biological, genetic, phenotypic, immunological, and clinical similarities to human gliomas. These features favor comparative approaches, leading to the treatment of canine oncological patients to achieve translational applications to the human clinic. The systemic administration of oncolytic viruses presents a challenge due to their limitations in effectively targeting tumors and metastases. Therefore, the aim of this study is to evaluate the safety and antitumor activity of a virotherapy used in spontaneous canine tumors.MethodsTen dogs with high-grade rostrotentorial gliomas underwent weekly systemic endovenous cellular virotherapy with dCelyvir (canine mesenchymal stem cells infected with the canine oncolytic adenovirus ICOCAV17) for 8 weeks. Efficacy was determined in seven dogs according to the Response Assessment in Veterinary Neuro-Oncology criteria considering clinical status and MRI measurements. Medical history, physical and neurological examinations, and vaccination status were evaluated prior to and during follow-up. Safety was evaluated by physical examinations and hematological and biochemical changes in peripheral blood. Immune populations were analyzed by flow cytometry in peripheral blood and by gene expression and immunohistochemistry in the tumor microenvironment.ResultsThe treatment was well tolerated and major adverse effects were not observed. Two dogs had partial responses (76% and 86% reduction in tumor size), and 3/7 showed stable disease. ICOCAV17 was detected in peripheral blood in nine dogs, and a correlation between the ICOCAV17 particles and anti-canine adenovirus (CAV) antibodies was observed. ICOCAV17 was detected in 3/9 tumor tissues after necropsies. Regarding tumor-infiltrating lymphocytes, the dogs with disease stabilization and partial response tended to have reduced memory B-cell infiltration and increased monocyte/macrophage lineage cells.ConclusionsThese findings indicate that dCelyvir is safe and presents efficacy in canine rostrotentorial high-grade gliomas. These data are relevant to the ongoing phase Ib regulated human clinical trial that is administering this virotherapy to children, adolescents, and young adults with diffuse pontine glioma. Celyvir should be further explored as a treatment in veterinary and human neuro-oncology.

APA, Harvard, Vancouver, ISO, and other styles

46

Rhind, Susan M. "Veterinary Oncological Pathology – Current and Future Perspectives." Veterinary Journal 163, no. 1 (January 2002): 7–18. http://dx.doi.org/10.1053/tvjl.2001.0637.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Favril, Sophie, Eline Abma, Francesco Blasi, Emmelie Stock, Nausikaa Devriendt, Katrien Vanderperren, and Hilde de Rooster. "Clinical use of organic near-infrared fluorescent contrast agents in image-guided oncologic procedures and its potential in veterinary oncology." Veterinary Record 183, no. 11 (April 28, 2018): 354. http://dx.doi.org/10.1136/vr.104851.

Full text

Abstract:

One of the major challenges in surgical oncology is the intraoperative discrimination of tumoural versus healthy tissue. Until today, surgeons rely on visual inspection and palpation to define the tumoural margins during surgery and, unfortunately, for various cancer types, the local recurrence rate thus remains unacceptably high. Near-infrared (NIR) fluorescence imaging is an optical imaging technique that can provide real-time preoperative and intraoperative information after administration of a fluorescent probe that emits NIR light once exposed to a NIR light source. This technique is safe, cost-effective and technically easy. Several NIR fluorescent probes are currently studied for their ability to highlight neoplastic cells. In addition, NIR fluorescence imaging holds great promise for sentinel lymph node mapping. The aim of this manuscript is to provide a literature review of the current organic NIR fluorescent probes tested in the light of human oncology and to introduce fluorescence imaging as a valuable asset in veterinary oncology.

APA, Harvard, Vancouver, ISO, and other styles

48

Sultan, Faheem, and Bilal Ahmad Ganaie. "Comparative oncology: Integrating human and veterinary medicine." Open Veterinary Journal 8, no. 1 (February 8, 2018): 25. http://dx.doi.org/10.4314/ovj.v8i1.5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Argyle, D. J., and B. R. Madewell. "A landmark in Veterinary and Comparative Oncology." Veterinary and Comparative Oncology 1, no. 1 (March 2003): 1–2. http://dx.doi.org/10.1046/j.1476-5829.2003.00011.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Argyle, David J. "Veterinary and Comparative Oncology: onwards and upwards." Veterinary and Comparative Oncology 4, no. 1 (March 2006): 1. http://dx.doi.org/10.1111/j.1476-5810.2006.00094.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!